Latest News and Press Releases

This is the first NDA acceptance for BTK inhibitor orelabrutinib in autoimmune diseases. No BTK inhibitors have been approved in China for ITP.

Kneat shareholders elect board of directors, approve auditors at Kneat's Annual General Meeting today

Orelabrutinib (HIBRUKA®) has been approved by TGA in Australia, offering a new treatment option for patients with R/R MCL in the region.

Austin, TX, USA, May 26, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Bioprocess Automation Software Market Size, Trends and Insights By Type...

The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.

Envetec approval creates new alternative to centralized medical waste treatment in Massachusetts.

Two of the world’s leading specialist healthcare investors with over $21 billion AUM are joining forces to create the largest dedicated healthcare investment manager globallyTogether, the group will...

Two of the world’s leading specialist healthcare investors with over $21 billion AUM are joining forces to create the largest dedicated healthcare investment manager globallyTogether, the group will...

PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and...

ALBANY, N.Y., May 19, 2026 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading global research, development and manufacturing organization, today announced the completion of its upgrade to its...